Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval Pharmaceutical TechnologyIonis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage.CardiovascularRead full story pharminent June 26, 2026 (Last updated: July 1, 2026) Pharmaceutical Technology Ionis has forecast peak sales of $2bn for Tryngolza as it seeks to harness first-mover advantage. Cardiovascular Read full story Post navigation Previous: Ionis grants Recordati rights to zilganersen for Alexander diseaseNext: Immunai and Boehringer partner to identify T-cell targets Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026